	A. Un-Audited Financial Resu			(Rs. in Lacs		
Sr. No). Particulars	3 Months ended 30.06.2013 (Unaudited)	Corresponding 3 months ended 30.06.2012 (Unaudited)	3 Months ended 31.03.2013 (Audited) (Refer Note No. 2)	Year Ended 31.03.2013 (Audited)	
1	Sales/Income from operation(Net of Excise duty)	1835,47	2375.92			
2	Other Operating Income	8.93	49.76	4590.55	12525.8	
3	Total Net Income from Operation	1844.40		26.67	104.3	
4	Expenditure		2720.00	4617.22	12630.1	
	(a) Increase / decrease in stock in trade & work in					
	progress	(384.99)	667.50	1307.55	2006 0	
	(b) Consumption of raw materials	1786.55	1360.44	2711,32	2005.28 8104.06	
	(c) Employees Cost	244.27	218.31	261.41	946.32	
	(d) Depreciation	98.49	93,41	100.62	393.97	
	(e) Other expenditure	461.76	452.80	437.34	1911.19	
		2206.08	2792.46	4818.24	13360.82	
5	Profit(+)/Loss(-) from operations before Other			1010.24	13300.62	
6	income,Finance cost and Exceptional Items(3-4) Other income	(361.68)	(366.78)	(201.02)	(730.63)	
Ť	Profit (+) / Loss (-) from ordinary activities before	1.98	0.99	50.86	52.96	
7	Finance Cost & Exceptional Items(5+6)	1				
8	Finance Cost & Exceptional items(5+6)	(359.70)	(365.79)	(150,16)	(677.67)	
<u> </u>	Profit(+)/Loss(-) from ordinary activities after Finance	226.86	236.89	253.20	1002.24	
9	cost & Exceptional Items(7-8)				7332.121	
10	Exceptional Items	(586.56)	(602.68)	(403.36)	(1679.91)	
11	Profit(+)/Loss(-) before Tax (9-10)	0.00	0.00	0.00	0.00	
12	Tax Expenses(incl Deferred Tax)	(586.56)	(602.68)	(403.36)	(1679.91)	
13	Net Profit(+)/Loss(-) after Tax (11-12)	0.00	0.00	(499.98)	(499.98)	
14	Extraordinary Items	(586.56)	(602.68)	96.62	(1179.93)	
15	Net Profit(+)/Loss(-) for the period(13-14)	0.00	0.00	0.00	0.00	
16	Paid up Equity Share Capital (face value Rs 10/-each)	(586.56) 1317.82	(602.68)	98.62	(1179.93)	
. !	Reserves excluding Revaluation Reserves as per	1317.02	1317.82	1317.82	1317.82	
2	balance sheet of previous accounting year.	0.00	2.22			
13	Earning per share (EPS)	0.00	0.00	0.00	1308.40	
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year				····	
- 10	(not to be annualized)	(4.45)	(4.57)		I	
מן	b) Basic and diluted EPS after extraordinary items for		(4.57)	0.73	(8.96)	
	he period, for the year to date and for the previous year	ĺ		İ		
15	not to be annualized)	(4.45)	(4.57)	0.70		
4 1	Non Promoters Shareholding	<u>, , , , , , , , , , , , , , , , , , </u>		0.73	(8.96)	
<u> </u>	Number of shares	7548453	7548453	7548453	7540450	
_ +:	Percentage of shareholding	57,28	57.28	57.28	7548453	
F S S D N N P SI	Promoters and Promoter group Shareholding			37.20	57.28	
) Pledged/ Encumbered					
	Number of Shares	5448708	1441095	5448708	5448708	
	Percentage of Shares (as a % of the total				5740700	
	hareholding of promoter & promoter group	96.78	25.59	96.78	96.78	
	ercentage of Shares (as a % of the total				80.70	
	hare capital of the company)	41.35	10.94	41.35	41.35	
) Non-encumbered				71.33	
	umber of Shares	181087	4188700	181087	181087	
	ercentage of Shares (as a % of the total				101007	
	hareholding of promoter & promoter group)	3.22	74.41	3.22	3,22	
	ercentage of Shares (as a % of the total			7	٧,22	
191	nare capital of the company)	1.37	31.78	1.37	1.37	

Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 13th August, 2013
- The financial results for the quarter ended 31st March 2013 are balancing figures between audited results for the full financial year 2 and published year to date figure upto the third quarter of the relevant financial year. 3
- During the Quarter ended 30th June 2013, 0 Investor complaint were received, all of which have been attended by the company. No complaints were pending at the beginning or at the end of the quarter.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk Drugs "the disclosure requirement of Accounting Standard(AS-17) "Segment Reporting" is not applicable
- 5 Previous year figures are regrouped wherever necessary.

ASSOC

FR.N.:106405W 31/33, Dr. M. B.

Velkar St.,

BHARAT

Place: Mumbai Date: 13.08.2013

For MILWANI ASSOCIATES Chartered Accountants akesh K. Milwani) Proprietor Mumbai-400 002 Membership No.: 36099 F.R.N.:106405W

On behalf of Board of Directors For Mangalam Drugs & Organics Ltd

(Shri Govardhan M.Dhoot) DIRECTOR

MILWANI ASSOCIATES CHARTERED ACCOUNTANTS

18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002. Tel.: 22036132/9821162679 E-mail: rakesh_milwani@hotmail.com

To The Secretary Stock Exchange, Mumbai Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001.

National Stock Exchange of India Limited "Exchange Plaza", Bandra - Kurla Complex, Bandra (E), Mumbai - 400 051.

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of Mangalam Drugs & Organics Ltd. having its registered office at 292, Princess Street, Second Floor, Near Flyover, Mumbai - 400 002; for the quarter ended 30th June, 2013 except for the disclosures regarding Public share holding' and 'Promoter and Promoter group share holding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material section of the second of

> FPN-106405W 31/33. Dr. M. B. Velkar St., Mumbai-400 002

BHARAT

Place : Mumbai

Date : 13th August, 2013.

CREATING MILWARD TETOR: MILWANRASSOCTATES

Chartered / Countaints

Membership No.36099 Firm Registration No.106405W